AroCell: Changes to the Case

Research Update

2020-06-30

07:20

Redeye significantly raises its Base Case for AroCell, given fundamental changes to the case following recent FDA filing in combination with close discussions with management. The company is transitioning to a more commercially oriented business with anticipated key activities in the coming 6-9 months. At a current market capitalization of roughly SEK 130m, we see great upside in the stock on all horizons.

Oscar Bergman

Disclosures and disclaimers